Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

TARA

Protara Therapeutics (TARA)

Protara Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:TARA
DateTimeSourceHeadlineSymbolCompany
01/05/20244:35PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARAProtara Therapeutics Inc
01/05/20244:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARAProtara Therapeutics Inc
01/05/20244:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARAProtara Therapeutics Inc
11/30/20238:30AMGlobeNewswire Inc.Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic OncologyNASDAQ:TARAProtara Therapeutics Inc
11/15/202312:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:TARAProtara Therapeutics Inc
11/03/20238:31AMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:TARAProtara Therapeutics Inc
11/03/20238:20AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TARAProtara Therapeutics Inc
11/03/20238:10AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:TARAProtara Therapeutics Inc
11/03/20238:00AMGlobeNewswire Inc.Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business UpdateNASDAQ:TARAProtara Therapeutics Inc
10/23/20238:00AMGlobeNewswire Inc.Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic MalformationsNASDAQ:TARAProtara Therapeutics Inc
09/20/20238:30AMGlobeNewswire Inc.Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in SituNASDAQ:TARAProtara Therapeutics Inc
09/05/20237:30AMGlobeNewswire Inc.Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:TARAProtara Therapeutics Inc
08/03/20238:20AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TARAProtara Therapeutics Inc
08/03/20238:12AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:TARAProtara Therapeutics Inc
08/03/20238:00AMGlobeNewswire Inc.Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business UpdateNASDAQ:TARAProtara Therapeutics Inc
07/18/20234:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARAProtara Therapeutics Inc
07/05/20234:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARAProtara Therapeutics Inc
06/27/20237:26PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:TARAProtara Therapeutics Inc
06/08/20234:11PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:TARAProtara Therapeutics Inc
06/08/20234:11PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:TARAProtara Therapeutics Inc
06/08/20234:11PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:TARAProtara Therapeutics Inc
06/08/20234:11PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:TARAProtara Therapeutics Inc
06/08/20234:11PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:TARAProtara Therapeutics Inc
06/08/20234:11PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:TARAProtara Therapeutics Inc
06/08/20234:11PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:TARAProtara Therapeutics Inc
06/08/20234:11PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:TARAProtara Therapeutics Inc
06/08/20234:07PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:TARAProtara Therapeutics Inc
05/15/20238:00AMGlobeNewswire Inc.Protara Therapeutics Announces Dosing of First Patients in Phase 1b ADVANCED-1EXP Trial of TARA-002 in NMIBC Patients with Carcinoma in SituNASDAQ:TARAProtara Therapeutics Inc
05/04/20238:11AMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:TARAProtara Therapeutics Inc
05/04/20238:00AMGlobeNewswire Inc.Protara Therapeutics Announces First Quarter 2023 Financial Results and Business UpdateNASDAQ:TARAProtara Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:TARA